Zymeworks Licenses Experimental Lung Cancer Drug to Roche in Deal Worth Up to $813 Million
Roche gained global rights to develop and commercialize Zymeworks’ experimental lung cancer drug under a licensing deal worth up to $813 million.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.